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Abstract
Human albumin is the most abundant protein in sera and a valuable biomarker in monitoring a variety of dis-
eases. In this study we investigated the relationship between serum albumin concentrations and effects of ini-
tiation of highly active antiretroviral therapy (HAART). Serum albumin concentrations amongst 70 HIV-infected
patients from diverse ethnicities were analyzed, in the absence of any other confounding comorbidities, over
a period of 8 years in South East London, United Kingdom. Serum albumin data was collected, on average,
every 4–6 weeks during routine visits. Serum albumin was measured prior to starting HAART, and measured
at the ﬁrst clinic visit after commencing HAART. These were compared to a control group of untreated individ-
uals. Based on our analyses we conclude that serum albumin concentrations increase signiﬁcantly after the ini-
tiation of therapy.
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Introduction
A link between circulating albumin levels, infection,
and mortality has been documented,1,2 with serum al-
bumin concentrations decreasing signiﬁcantly during
periods of stress, trauma, or sepsis.3 Albumin can
also be lost into the intestine, where digestion releases
amino acids and peptides that can be reabsorbed in
healthy subjects.4 In an intensive care setting, mortality
and infection rates increased in critically ill patients
with hypoalbuminaemia (below 35g/L).1 Serum albu-
min has been recognized as a prognostic indicator in
human immunodeﬁciency virus infection (HIV).5–7
Graham et al. (2007) reported on the association be-
tween serum albumin and HIV in a cohort of HIV-
positive women in Kenya: each 1g/L decrease in
serum albumin was associated with a 13% increase in
risk of progression to a CD4 T-cell count of < 200
cells/mm3.8
There is just one report on the effect of highly ac-
tive antiretroviral therapy (HAART) on serum albumin
concentrations amongst those infected with HIV.
Chauhan et al. 2011 studied HIV-positive Indian pa-
tients and found that serum albumin levels increased
after the commencement of HAART.9 In the long
term, HAART has the potential to cause hepatotoxicity
and may impair albumin production.10
Our study investigated serum albumin concentra-
tions in a cohort of HIV-positive patients in South
East London, United Kingdom.We investigated whether
the initiation of HAART impacts upon serum albumin
concentrations, compared to a control group of un-
treated HIV-positive individuals.
Materials and Methods
Seventy HIV-1 positive patients recruited to the Infec-
tious Diseases BioBank (IDB)11 at King’s College
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London were investigated. Thirty-nine of these patients
commenced HAART, and baseline serum albumin lev-
els immediately prior to treatment and the ﬁrst mea-
surement after treatment were used, generally within
4–6 weeks. These were analyzed against the control
group of 31 untreated patients, where the baseline
serum albumin level was the earliest recorded measure-
ment. The median measurement from multiple clinic
visits was taken in the control group to compare to
post-HAART serum albumin in the treated group. Of
the 70 patients, none were known to be hepatitis B
virus positive. Data between July 2004 and June 2013
was included, and on average, serum albumin concen-
trations were measured every 4–6 weeks for each pa-
tient. Normal serum albumin concentrations were
considered to be between 35 and 50g/L.12
Baseline CD4 T-cell count data was measured in the
treated cohort immediately prior to treatment, and
measured again after treatment, generally within 4–6
weeks. These were analyzed against the untreated con-
trol group, where the baseline CD4 T-cell count was the
earliest recorded measurement. The median measure-
ment from multiple clinic visits was taken in the con-
trol group to compare to post-HAART CD4 T-cell
count in the treated group. Serum albumin concentra-
tions and CD4 T-cell counts were measured by GSTS
Pathology. Patients infected with a variety of HIV
clade strains were represented in both cohorts.
Ethical approval for all aspects of this study was
obtained through the King’s College London Infectious
Disease BioBank Local Research Ethics Committee
(under the authority of the Southampton and South
West Hampshire Research Ethics Committee—
approval REC09/H0504/39). Statistical testing was done
by comparing the mean change from baseline level of
serum albumin/CD4 T-cell count to post-HAART or
median measurement between treatment groups, using
a t test with change scores, and statistical analyses were
performed using Stata 13.1.
Results
Of the 70 patients, the majority were men (85.7%) and
white (67.1%), followed by black Africans (14.3%) and
other black (10%). The mean age at diagnosis was
33.7 (– 8.4) years. Patient characteristics are listed in
Table 1.
There was sufﬁcient data to compare initiation of
HAART for 39 patients. The majority of patients
were male (92.3%) and white (76.9%). The mean age
at diagnosis was 35.5 ( – 9.3) years, and the mean age
at commencement of HAART in the 39 patients was
38.6 (– 9.6) years.
The mean change in serum albumin between baseline
and median in the untreated group was 0.24g/L (95%
conﬁdence interval [95% CI] 0.88 to 1.36), compared
with pre- and post-treatment change of 2.15 g/L (95%
CI 1.06 to 3.25) in the treated group. The mean change
was 1.91g/L (95% CI 0.36 to 3.47) in the treated group
compared with the untreated group. There was strong
evidence that this change between the two time points
differed between the treated and untreated groups
( p= 0.0166) (Fig. 1). The mean change in CD4 T-cell
count between baseline and median in the untreated
Table 1. Patient Characteristics
Untreated
(n= 31)
Treated
(n = 39)
Mean age at diagnosis,
years (SD)
31.5 ( – 6.5) 35.5 ( – 9.3)
Mean age at commencement
of HAART, years (SD)
N/A 38.6 ( – 9.6)
Mean CD4 T-cell count,
baseline, cells/mm3 (SD)
646.2 ( – 255.3) 299.5 ( – 124.1)
Mean CD4 T-cell count,
median/after treatment,
cells/mm3 (SD)
664.6 ( – 293.9) 470.3 ( – 201.8)
Sex, n (%)
Male 24 (77.4%) 36 (92.3%)
Female 7 (22.6%) 3 (7.7%)
Ethnicity, n (%)
White 17 (54.8%) 30 (76.9%)
Asian 0 1 (2.5%)
Black, African 7 (22.6%) 3 (7.7%)
Black, other 6 (19.4%) 1 (2.5%)
Mixed/other 0 4 (10.4%)
N/A 1 (3.2%) 0
SD, standard deviation; HAART, highly active antiretroviral therapy.
FIG. 1. Mean serum albumin concentrations.
HAART, highly active antiretroviral therapy.
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group was 2.16 cells/mm3 (95% CI 83.01 to 87.24),
compared to pre- and post-treatment change in the
treated group of 191.16 cells/mm3 (95% CI 126.57 to
255.75). Strong evidence suggests that this change be-
tween the two time points differed between the treated
and untreated groups ( p= 0.0005) (Fig. 2).
Discussion
Our data shows that serum albumin levels increase signif-
icantly after commencement of HAART, compared with
a control cohort of untreated individuals. In comparison
with the closest equivalent study, our patients were
more ethnically diverse and presented with no hypoalbu-
minaemia at the baseline visit.9 The difference in baseline
hypoalbuminaemia between our cohort and the Indian
cohort may be due to dietary, geographic, and/or ethnic
group differences. Additionally, there is little information
on the HIV-1 clade in the other comparable studies to be
able to investigate any potential correlation.
HAART has a profound impact on HIV, lowering
viral loads and allowing CD4 T-cells to increase in
number.13 Our data shows a signiﬁcant increase in
CD4 T-cell count after the initiation of HAART. In pa-
tients coinfected with other viruses, the beneﬁcial effect
of HAART on the immune system can result in lower-
ing of viral loads in chronic infections such as hepatitis
B14, C15, and G16. Despite the number of studies look-
ing into coinfected individuals, most patients are likely
to be HIV positive and hepatitis B/C negative, and the
effect of HAART on liver function in monoinfected pa-
tients is of greatest clinical relevance.
Serum albumin levels are a good prognostic marker
in HIV infection, with studies from both the pre-
HAART6 and post-HAART7 eras supporting their rel-
evance in HIV medicine. Mehta et al. (2006) reported
that hypoalbuminaemia after HIV seroconversion
was associated with faster disease progression, and a
likely consequence of HIV infection.17 Additionally,
in resource-poor settings, the potential use of serum al-
bumin levels as an alternative to the more costly and
specialized CD4 T-cell counts and viral load assays
has been recognized.18,19 However, serum albumin lev-
els are unlikely to respond as acutely as CD4 T-cell
count and viral load assays, and where available,
these should always be used as ﬁrst line assays.
We hypothesize that in our control group of untreated
individuals, the stress of their HIV infection may affect
the rate of production for some proteins such as albumin,
or increase their rate of loss. The observed differences in
albumin levels may be due to multiple factors. Some of
the possible explanations for the change in serum albu-
min levels include: (1) the fact that it is a ‘‘negative’’
acute phase protein and levels fall during inﬂammation,
(2) excessive excretion via the kidney, (3) loss to the
bowel, and (4) liver disease. The latter is unlikely as we
excluded patients with known hepatitis B or C virus infec-
tions. Integrity of the bowel wall is damaged during the
acute phase of HIV infection resulting in bacterial trans-
location into the plasma, and HIV infection causes in-
ﬂammation of the bowel. The paradox in both of these
cases is that such damage is believed to occur early during
the disease process, yet we noted that albumin concentra-
tions were lowest amongs those with chronic disease.
The presented data supports an observed beneﬁt
of HAART on circulating serum albumin levels and
CD4 T-cell count. The relationship between HAART
and the liver, the site of albumin synthesis, is a balance
of the beneﬁciary effect of immune system reconstitu-
tion versus the potential long-term toxic nature of the
antiviral drugs that constitute HAART.20 Although an
increase of 2.15g/L may seem clinically small, this rise
in serum albumin level is a likely indicator of the overall
beneﬁt of HAART in mitigating the systemic effects of
HIV infection, as described above. In conclusion, com-
mencement of HAART in HIV infected individuals ex-
hibits beneﬁts to the circulating serum albumin levels.
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